

Table 1.17

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 18 SEER Areas, 2012-2014

| Site | All Races | | Whites | | Blacks | |
|--|-----------|------------------|---------|------------------|---------|------------------|
| | Percent | (95% C.I.) | Percent | (95% C.I.) | Percent | (95% C.I.) |
| All Sites | 37.65 | (37.53, 37.76) | 38.25 | (38.13, 38.38) | 34.01 | (33.69, 34.34) |
| Invasive and In Situ | 40.85 | (40.74, 40.97) | 41.46 | (41.33, 41.60) | 36.24 | (35.91, 36.58) |
| Oral Cavity and Pharynx | 0.68 | (0.67, 0.70) | 0.70 | (0.69, 0.72) | 0.49 | (0.45, 0.53) |
| Esophagus | 0.22 | (0.21, 0.23) | 0.22 | (0.21, 0.23) | 0.24 | (0.22, 0.27) |
| Stomach | 0.65 | (0.64, 0.67) | 0.55 | (0.54, 0.57) | 0.82 | (0.77, 0.88) |
| Colon and Rectum | 4.15 | (4.12, 4.19) | 4.08 | (4.04, 4.12) | 4.39 | (4.27, 4.51) |
| Invasive and In Situ | 4.28 | (4.24, 4.31) | 4.20 | (4.15, 4.24) | 4.55 | (4.43, 4.67) |
| Liver and Intrahepatic Bile Duct | 0.60 | (0.59, 0.62) | 0.54 | (0.52, 0.55) | 0.56 | (0.52, 0.60) |
| Pancreas | 1.54 | (1.52, 1.57) | 1.51 | (1.48, 1.54) | 1.71 | (1.63, 1.79) |
| Larynx | 0.12 | (0.12, 0.13) | 0.13 | (0.12, 0.14) | 0.16 | (0.14, 0.19) |
| Invasive and In Situ | 0.13 | (0.13, 0.14) | 0.14 | (0.13, 0.15) | 0.17 | (0.15, 0.20) |
| Lung and Bronchus | 5.95 | (5.90, 6.00) | 6.21 | (6.16, 6.26) | 5.24 | (5.11, 5.37) |
| Melanoma of the Skin | 1.72 | (1.69, 1.74) | 2.04 | (2.01, 2.07) | 0.10 | (0.09, 0.13) |
| Invasive and In Situ | 3.03 | (3.00, 3.06) | 3.50 | (3.46, 3.54) | 0.14 | (0.12, 0.17) |
| Breast | 12.41 | (12.35, 12.48) | 12.68 | (12.61, 12.75) | 11.39 | (11.22, 11.57) |
| Invasive and In Situ | 14.73 | (14.66, 14.80) | 14.95 | (14.87, 15.02) | 13.66 | (13.47, 13.86) |
| Cervix Uteri | 0.62 | (0.61, 0.63) | 0.60 | (0.58, 0.61) | 0.75 | (0.70, 0.79) |
| Corpus and Uterus, NOS | 2.85 | (2.82, 2.88) | 2.92 | (2.88, 2.95) | 2.64 | (2.55, 2.73) |
| Invasive and In Situ | 2.87 | (2.84, 2.90) | 2.94 | (2.90, 2.97) | 2.66 | (2.58, 2.75) |
| Ovary ^a | 1.27 | (1.25, 1.29) | 1.33 | (1.31, 1.35) | 0.95 | (0.90, 1.01) |
| Urinary Bladder (Invasive and In Situ) | 1.12 | (1.10, 1.14) | 1.19 | (1.17, 1.21) | 0.80 | (0.74, 0.85) |
| Kidney and Renal Pelvis | 1.20 | (1.18, 1.22) | 1.24 | (1.21, 1.26) | 1.25 | (1.19, 1.31) |
| Brain and Other Nervous System | 0.54 | (0.53, 0.56) | 0.60 | (0.58, 0.61) | 0.31 | (0.28, 0.34) |
| Thyroid | 1.79 | (1.77, 1.81) | 1.89 | (1.87, 1.92) | 1.11 | (1.06, 1.16) |
| Hodgkin Lymphoma | 0.19 | (0.18, 0.19) | 0.20 | (0.19, 0.21) | 0.17 | (0.15, 0.19) |
| Non-Hodgkin Lymphoma | 1.87 | (1.84, 1.89) | 1.96 | (1.93, 1.99) | 1.21 | (1.15, 1.27) |
| Myeloma | 0.65 | (0.63, 0.66) | 0.57 | (0.56, 0.59) | 1.24 | (1.18, 1.31) |
| Leukemia | 1.26 | (1.23, 1.28) | 1.32 | (1.29, 1.34) | 0.91 | (0.86, 0.97) |
| Acute Lymphocytic Leukemia | 0.12 | (0.11, 0.12) | 0.13 | (0.12, 0.13) | 0.07 | (0.06, 0.09) |
| Chronic Lymphocytic Leukemia | 0.44 | (0.43, 0.46) | 0.48 | (0.46, 0.49) | 0.28 | (0.25, 0.32) |
| Acute Myeloid Leukemia | 0.43 | (0.42, 0.45) | 0.45 | (0.43, 0.46) | 0.34 | (0.31, 0.38) |
| Chronic Myeloid Leukemia | 0.16 | (0.15, 0.16) | 0.16 | (0.15, 0.17) | 0.14 | (0.12, 0.16) |
| Kaposi Sarcoma | 0.05 | (0.05, 0.06) | 0.06 | (0.05, 0.06) | 0.03 | (0.02, 0.04) |
| Mesothelioma | 0.01 | (0.01, 0.01) | 0.01 | (0.01, 0.01) | 0.01 | (0.01, 0.02) |

Devcan Version 6.7.5, April 2017, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

^a Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 18 SEER Areas, 2012-2014

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|--|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 33.43 (33.01, 33.86) | 28.97 (27.44, 30.67) | 34.62 (34.25, 35.01) |
| Invasive and In Situ | 35.76 (35.33, 36.20) | 30.38 (28.84, 32.11) | 36.64 (36.26, 37.03) |
| Oral Cavity and Pharynx | 0.64 (0.58, 0.71) | 0.62 (0.45, 1.07) | 0.49 (0.44, 0.55) |
| Esophagus | 0.14 (0.11, 0.18) | 0.17 (0.08, 0.58) | 0.17 (0.14, 0.21) |
| Stomach | 1.40 (1.30, 1.51) | 1.18 (0.83, 1.77) | 1.19 (1.12, 1.28) |
| Colon and Rectum | 4.10 (3.94, 4.27) | 4.59 (3.95, 5.43) | 3.91 (3.78, 4.06) |
| Invasive and In Situ | 4.21 (4.05, 4.38) | 4.62 (3.98, 5.47) | 4.02 (3.88, 4.17) |
| Liver and Intrahepatic Bile Duct | 1.24 (1.15, 1.33) | 1.12 (0.85, 1.62) | 1.13 (1.06, 1.20) |
| Pancreas | 1.69 (1.58, 1.81) | 1.11 (0.79, 1.69) | 1.68 (1.59, 1.78) |
| Larynx | 0.04 (0.02, 0.07) | 0.05 (0.01, 0.47) | 0.06 (0.05, 0.09) |
| Invasive and In Situ | 0.05 (0.03, 0.08) | 0.05 (0.01, 0.47) | 0.07 (0.05, 0.10) |
| Lung and Bronchus | 4.51 (4.34, 4.69) | 3.56 (3.03, 4.31) | 3.57 (3.44, 3.71) |
| Melanoma of the Skin | 0.16 (0.13, 0.21) | 0.49 (0.33, 0.93) | 0.56 (0.51, 0.62) |
| Invasive and In Situ | 0.20 (0.17, 0.25) | 0.69 (0.50, 1.15) | 0.90 (0.84, 0.98) |
| Breast | 10.54 (10.34, 10.75) | 7.68 (7.02, 8.53) | 9.93 (9.75, 10.11) |
| Invasive and In Situ | 13.07 (12.85, 13.30) | 9.05 (8.34, 9.94) | 11.76 (11.57, 11.95) |
| Cervix Uteri | 0.62 (0.57, 0.68) | 0.68 (0.49, 1.12) | 0.85 (0.81, 0.91) |
| Corpus and Uterus, NOS | 2.31 (2.22, 2.41) | 1.98 (1.67, 2.52) | 2.53 (2.45, 2.63) |
| Invasive and In Situ | 2.32 (2.23, 2.42) | 1.99 (1.68, 2.52) | 2.55 (2.46, 2.64) |
| Ovary ^c | 1.13 (1.05, 1.21) | 1.10 (0.85, 1.59) | 1.25 (1.18, 1.32) |
| Urinary Bladder (Invasive and In Situ) | 0.72 (0.65, 0.81) | 0.67 (0.40, 1.22) | 0.79 (0.72, 0.87) |
| Kidney and Renal Pelvis | 0.81 (0.74, 0.89) | 1.23 (0.92, 1.77) | 1.42 (1.35, 1.49) |
| Brain and Other Nervous System | 0.36 (0.32, 0.41) | 0.24 (0.14, 0.65) | 0.47 (0.43, 0.52) |
| Thyroid | 1.80 (1.73, 1.88) | 1.34 (1.10, 1.82) | 1.79 (1.73, 1.85) |
| Hodgkin Lymphoma | 0.09 (0.07, 0.12) | 0.17 (0.08, 0.59) | 0.18 (0.16, 0.21) |
| Non-Hodgkin Lymphoma | 1.61 (1.51, 1.72) | 1.22 (0.93, 1.75) | 2.01 (1.92, 2.11) |
| Myeloma | 0.47 (0.42, 0.53) | 0.77 (0.54, 1.26) | 0.66 (0.61, 0.72) |
| Leukemia | 0.85 (0.78, 0.93) | 0.68 (0.49, 1.14) | 1.07 (1.01, 1.15) |
| Acute Lymphocytic Leukemia | 0.10 (0.09, 0.13) | 0.13 (0.07, 0.54) | 0.18 (0.16, 0.20) |
| Chronic Lymphocytic Leukemia | 0.10 (0.08, 0.13) | 0.13 (0.06, 0.55) | 0.25 (0.22, 0.30) |
| Acute Myeloid Leukemia | 0.44 (0.39, 0.50) | 0.24 (0.13, 0.67) | 0.40 (0.36, 0.45) |
| Chronic Myeloid Leukemia | 0.12 (0.10, 0.16) | 0.09 (0.05, 0.50) | 0.13 (0.11, 0.16) |
| Kaposi Sarcoma | 0.04 (0.02, 0.08) | 0.00 (0.00, 0.43) | 0.06 (0.04, 0.08) |
| Mesothelioma | 0.01 (0.00, 0.03) | 0.02 (0.00, 0.45) | 0.04 (0.02, 0.06) |

Devcan Version 6.7.5, April 2017, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.^c Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.